Latest news with #REC-4881
Yahoo
05-05-2025
- Business
- Yahoo
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results
Recursion Pharmaceuticals has demonstrated resilience amid recent financial challenges, with the stock experiencing a 34% increase over the last month. This notable price movement may reflect the market's positive reception to promising developments in their Phase 1b/2 TUPELO trial for REC-4881, despite reporting a significant net loss increase. The trial results showing a 43% reduction in polyp burden for FAP and regulatory recognition of REC-4881 highlight the company's focus on addressing rare diseases. While broader market trends remained largely stable, Recursion's performance illustrates its potential appeal to investors amidst a mixed company earnings landscape. We've spotted 4 weaknesses for Recursion Pharmaceuticals you should be aware of, and 2 of them make us uncomfortable. We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent innovations from Recursion Pharmaceuticals, particularly the positive Phase 1b/2 TUPELO trial results, have generated market enthusiasm, propelling a significant short-term share price increase. However, over a longer time frame of three years, the company's total return, including share price and dividends, was 2.52%, highlighting a modest performance amidst a challenging biotechnology landscape. Compared to the broader U.S. Biotechs industry, Recursion's shares underperformed, as the industry saw a decline of 6.9% in the past year, showcasing Recursion's relative resilience despite its financial setbacks. The market's response to the trial outcomes suggests potential upside for the company's future revenue and earnings forecasts, driven by increased investor confidence in its drug discovery pipeline. These strong trial results could bolster Recursion's revenue projections, supporting the assumption of a projected annual growth rate of 37.9%. However, despite this optimism, the firm remains unprofitable with earnings forecasted to decline by an average of 2.2% per year over the next three years. Currently trading at US$5.72, Recursion's share price remains below the consensus analyst price target of US$8.71, indicating a potential 34.4% upside. Yet, given the complicated projections involving a high price-to-earnings ratio of 124.1x by 2028, it's crucial for investors to appraise the assumptions underlying the analyses. The sensitivity of these projections to clinical outcomes, partnerships, and technological advancements underscores the nuanced dynamics at play in evaluating the company's future performance. Gain insights into Recursion Pharmaceuticals' future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:RXRX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Business Insider
05-05-2025
- Health
- Business Insider
Recursion announces preliminary results from Phase 1b/2 TUPELO trial
Recursion announced preliminary safety and efficacy results from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational, allosteric MEK1/2 inhibitor in development for Familial Adenomatous Polyposis. These data were presented in a late-breaking oral presentation at Digestive Disease Week, DDW, 2025 in San Diego, California. As of the March 17, 2025 data cutoff in the open-label Phase 2 portion of the TUPELO trial, treatment with REC-4881 led to a preliminary median 43% reduction to date in polyp burden at the Week 13 assessment among six efficacy-evaluable patients. Other investigational agents in separate studies have reported 20-30% polyp burden reduction in 6 months1. Five of the six patients experienced reductions in polyp burden ranging from 31% to 82%, while one patient showed a substantial increase of 595% from baseline. Additionally, three of six patients achieved a greater than or equal to1-point reduction in Spigelman stage; one patient had no change, one progressed from Stage II to IV, and one had no baseline stage but was classified as Stage II at Week 13.
Business Insider
23-04-2025
- Business
- Business Insider
Recursion to present clinical data from ongoing Phase 1b/2 trial of REC-4881
The company states: 'Recursion will present preliminary data during the 2025 Digestive Disease Week meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego. Currently, there are no FDA-approved therapies for FAP, a rare hereditary autosomal dominant colorectal cancer predisposition syndrome, affecting approximately 50,000 people in the US, France, Germany, Italy, Spain, and the UK. REC-4881 has been granted Fast Track and Orphan Drug designation by the U.S. Food and Drug Administration as well as Orphan Drug designation by the European Commission.' Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Yahoo
23-04-2025
- Business
- Yahoo
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego. 'We are pleased that DDW has recognized the importance of our data in addressing the unmet needs of the FAP patient population, where no FDA-approved therapies currently exist,' said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. 'MEK 1/2 inhibition for the potential treatment of FAP was identified through our AI-powered Recursion OS platform, which analyzed cellular models of APC gene loss to uncover a potential first-in-disease treatment. We look forward to sharing our preliminary findings in our upcoming DDW presentation in May.' Currently, there are no FDA-approved therapies for FAP, a rare hereditary autosomal dominant colorectal cancer predisposition syndrome, affecting approximately 50,000 people in the US, France, Germany, Italy, Spain, and the UK. REC-4881 has been granted Fast Track and Orphan Drug designation by the U.S. Food and Drug Administration as well as Orphan Drug designation by the European Commission. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule MEK 1/2 inhibitor. The platform analyzed cellular models of APC gene loss—the root cause of FAP—to identify compounds that suppress the disease-inducing effects of APC mutations. In the late-breaking abstract, Recursion presented preliminary data as of February 7, 2025, showing that 13 patients received 4 mg of REC-4881 QD, with 84.6% experiencing at least one treatment-related adverse event (TRAE). The most commonly reported TRAE was rash / dermatitis acneiform, primarily Grade 1 or 2. Of the 5 efficacy-evaluable patients, they experienced a greater than 30% median reduction in total polyp burden after 12 weeks of treatment. The DDW data presentation will include new results from a later data cut-off, as well as the data included in the accepted abstract. For more information about Digestive Disease Week please visit Presentation Title: Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Preliminary Safety and Efficacy Data Session 0006, Presentation ID 354a: May 4, 2025 from 9:15 AM to 9:30 AM PDT Presenter: N Jewel Samadder, M.D., Mayo Clinic Comprehensive Cancer Center About the TUPELO Trial The Phase 1b/2 TUPELO trial is evaluating REC-4881 as a potential treatment for patients with FAP post-colectomy/proctocolectomy. This multicenter, open-label study assesses the efficacy, safety, and pharmacokinetics of REC-4881 in this patient population. About Digestive Disease WeekDigestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases nearly 6,000 abstracts and over 1,000 invited talks on the latest advances in GI research, medicine and technology. More information can be found at About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at or connect on X (formerly Twitter) and LinkedIn. Forward-Looking StatementsThis document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC-4881, including the potential to be a first-in-disease treatment; the timing of and outcomes of the TUPELO clinical trial; the effects of our platform on trial outcomes; the potential size of the market opportunity for our drug candidates; the timing and presentation of preliminary data at the 2025 Digestive Disease Week meeting; Recursion's leadership of the TechBio space; the Recursion OS and other technologies; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as 'plan,' 'will,' 'expect,' 'anticipate,' 'intend,' 'believe,' 'potential,' 'continue,' and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading 'Risk Factors' in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024. All forward-looking statements are based on management's current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law. CONTACT: Media Contact Media@ Investor Contact Investor@
